FDA blocks approval of Regeneron's blood cancer drug over confirmatory trial enrollment

Regeneron may have gotten ahead of itself with the early filing of bispecific antibody odronextamab to regulators. In a move that might not surprise keen FDA watchers, the agency has issued two complete response letters over the timelines of ongoing phase 3 confirmatory trials for the drug.